Tenofovir-based pre-exposure prophylaxis (PrEP) revolutionized the global HIV prevention landscape. Prior to the proof-of concept trial in 2010, which demonstrated that tenofovir (TFV) could prevent sexual transmission of HIV, prevention options were largely limited to behavior change, condoms, and circumcision. Several subsequent studies evaluating oral tenofovir disoproxil fumarate (TDF) or the TDF/emtricitabine (FTC) combination as PrEP for HIV prevention provided evidence for regulatory approval and inclusion in national and international guidelines. By 2021, 1.5 million people had initiated oral tenofovir-based PrEP, contributing to declines in HIV incidence in some regions. Here we reflect on how oral tenofovir-based PrEP became an important component of combination HIV prevention programs across the globe.

中文翻译：

---

使用基于替诺福韦的暴露前预防来推进 HIV 预防。

基于替诺福韦的暴露前预防 (PrEP) 彻底改变了全球艾滋病毒预防领域。在 2010 年的概念验证试验证明替诺福韦 (TFV) 可以预防 HIV 的性传播之前，预防选择主要限于行为改变、避孕套和包皮环切术。随后的几项研究评估了口服富马酸替诺福韦酯 (TDF) 或 TDF/恩曲他滨 (FTC) 组合作为预防 HIV 的 PrEP，为监管部门批准和纳入国家和国际指南提供了证据。到 2021 年，已有 150 万人启动了基于口服替诺福韦的 PrEP，这有助于一些地区的 HIV 发病率下降。在这里，我们回顾了基于口服替诺福韦的 PrEP 如何成为全球艾滋病联合预防计划的重要组成部分。